Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Mechanism
Peptide GH secretagogue; acute endocrine response is not demonstrated muscle growth.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
Mentioned for GH, recovery and body composition; distinguish these uses from brief physiology experiments.
Human evidence
A study in six normal young men examined subcutaneous administrations over 24 hours: GH secretion increased without an IGF-1 change. It did not measure chronic functional benefit.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A study in six normal young men examined subcutaneous administrations over 24 hours: GH secretion increased without an IGF-1 change. It did not measure chronic functional benefit.
A study in six normal young men examined subcutaneous administrations over 24 hours: GH secretion increased without an IGF-1 change. It did not measure chronic functional benefit.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
1.5 mcg/kg · Amount per administration
- Frequency
- Two or three administrations over 24 hours
- Duration
- 24 hours
- Route
- Subcutaneous
- Context
- Six normal men; GH physiology, not chronic anabolic efficacy.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID11888836 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
A sample of six cannot delimit uncommon effects or long-term GH-axis safety; a one-day experiment does not establish metabolic neutrality.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID11888836 · Physiology experiment
Normal young men.
SC, 24 hours.
Increased GH secretion without an IGF-1 change.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 6
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Hexarelin · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID11888836
Maccario M, Veldhuis JD, Broglio F, Vito LD, Arvat E, Deghenghi R, Ghigo E.
October 16, 2026
- SEARCH-PUBMED-hexarelin
PubMed/MED targeted search: TITLE_ABS:hexarelin AND TITLE_ABS:healthy AND TITLE_ABS:men
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026